Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This position statement will address in an evidence-based approach some of the important issues and controversies of current drug treatment of depression such as the efficacy of antidepressants, their effect on suicidality and their place in a complex psychiatric treatment strategy including psychotherapy. The efficacy of antidepressants is clinically relevant. The highest effect size was demonstrated for severe depression. Based on responder rates and based on double-blind placebo-controlled studies, the number needed to treat (NNT) is 5–7 for acute treatment and four for maintenance treatment. Monotherapy with one drug is often not sufficient and has to be followed by other antidepressants or by comedication/augmentation therapy approaches. Generally, antidepressants reduce suicidality, but under special conditions like young age or personality disorder, they can also increase suicidality. However, under the conditions of good clinical practice, the risk–benefit relationship of treatment with antidepressants can be judged as favourable also in this respect. The capacity of psychiatrists to individualise and optimise treatment decisions in terms of ‘the right drug/treatment for the right patient’ is still restricted since currently there are no sufficient powerful clinical or biological predictors which could help to achieve this goal. There is hope that in future pharmacogenetics will contribute significantly to a personalised treatment. With regard to plasma concentration, therapeutic drug monitoring (TDM) is a useful tool to optimize plasma levels therapeutic outcome. The ideal that all steps of clinical decision-making can be based on the strict rules of evidence-based medicine is far away from reality. Clinical experience so far still has a great impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 1×
“given this diversity and complexity in the aetiopathogenesis of depression and the pharmacological mechanisms of antidepressants [19,23,41,42,76,178], there is a huge variation of different responses to treatment in general, as well as of different dispositions regarding the question as to which specific antidepressan…”
BackgroundKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503 · cited 1×
“Depression is one of the most prevalent psychiatric disorders [3,206] and leads to substantial suffering of the patients, a heavy burden for the family, a high risk of suicidal behaviour (lifetime risk of suicide up to 15%) and significant socioeconomic”
BackgroundKeller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331 · cited 2×
“[80] comparing the acute treatment with either nefazodone or a special short-term psychotherapy (CBASP) or both, COMBI was superior to medication alone in patients with the following diagnoses: (1) dysthymia with additional major depressive disorder (MDD), or (2) persisting MDD or (3) partially remitted MDD with poor…”
BackgroundResult
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“For a comprehensive discussion on the topic, see the Position Statement of the EPA on the value of antidepressants in the treatment of unipolar depression (Moller et al. 2012).”
BackgroundSelf-citationJesulola, E., Micalos, P., & Baguley, I. J. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.12.025 · Cited by 379
Lundgren, J. G., Dahlström, Ö., Andersson, G., Jaarsma, T., Kärner Köhler, A., & Johansson, P. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.5556 · Cited by 104
Croatto, G., Vancampfort, D., Miola, A., Olivola, M., Fiedorowicz, J. G., Firth, J., Alexinschi, O., Gaina, M. A., Makkai, V., Soares, F. C., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01770-w · Cited by 66
Zemplényi, A., Józwiak-Hagymásy, J., Kovács, S., Erdősi, D., Boncz, I., Tényi, T., Osváth, P., & Voros, V. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04078-9 · Cited by 23
“Health-economics studies have shown that the direct costs of treating depression are much less than the costs and social harm caused by untreated depression [4].”
Background
Metadata
- Authors
- Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2012-02
- Volume
- 27
- Issue
- 2
- Pages
- 114-128
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W1998805718
- Cited by
- 53
- References
- 51
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. https://app.cochat.ai/papers/10.1016/j.eurpsy.2011.08.002
- The paper
- Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012). Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2011.08.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.